China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round on Jan. 2 to fund development of its two lead cancer compounds, selinexor and ATG-008.

Boyu Capital and FountainVest led the round, with participation by Celgene Corp. (NASDAQ:CELG), WuXi Corporate Venture Fund, Taikang and existing investors Qiming Venture Partners and TF Capital. Qiming led Antengene’s $21 million series A round in 2017...